Glenmark Pharmaceuticals has informed that the Baddi manufacturing unit of the company was inspected by the leading European regulator, SUKL (State Institute for Drug control), Czech Republic in the week of October 21, 2019. The European regulator has just issued a certificate of compliance for the facility stating that it complies with the principles and guidelines of Good Manufacturing Practice laid down in the directive 2003/94/EC which stipulates the requirements to fulfill GMP recommendations of WHO.
The above information is a part of company’s filings submitted to BSE.